StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $0.43 on Thursday. The firm has a market capitalization of $6.22 million, a PE ratio of -0.27 and a beta of 1.80. The business’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.50. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.09. As a group, equities analysts anticipate that Aethlon Medical will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

Large investors have recently bought and sold shares of the stock. Allegiance Financial Group Advisory Services LLC acquired a new position in Aethlon Medical in the fourth quarter valued at $26,000. Renaissance Technologies LLC acquired a new position in Aethlon Medical in the fourth quarter valued at $25,000. Boothbay Fund Management LLC acquired a new position in Aethlon Medical in the fourth quarter valued at $186,000. Sassicaia Capital Advisers LLC acquired a new position in Aethlon Medical in the fourth quarter valued at $31,000. Finally, Virtu Financial LLC acquired a new position in Aethlon Medical in the fourth quarter valued at $81,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.